Physician profile
John R Bergquist
NPI 1750645529
$29,267.75
in general payments reported to CMS, 2019-2025
23 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 81% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,745 · 2022: $7,669 · 2023: $13K · 2024: $3,360 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $13K · Travel and Lodging: $3,212 · Food and Beverage: $2,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $13,000.00 |
| Travel and Lodging | $3,212.01 |
| Food and Beverage | $2,642.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $27,607.18 | 2019-2025 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $303.86 | 2022-2025 | Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.72 | 2023-2025 | Xifaxan, Trulance, Aldara |
| Takeda Pharmaceuticals U.S.A., INC. | $165.51 | 2022-2025 | Entyvio |
| Madrigal Pharmaceuticals | $156.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $147.20 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $91.39 | 2024-2025 | Stelara, Tremfya |
| Myriad Genetic Laboratories, INC. | $88.40 | 2022 | |
| Lilly USA, LLC | $82.99 | 2025 | Omvoh |
| Integra Lifesciences Corporation | $76.28 | 2023 | Duraseal Exact Spinal Sealant System, Codman Certas, Cusa Clarity |
| Veloxis Pharmaceuticals, INC. | $61.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $49.79 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $49.40 | 2023 | Andexxa |
| Qol Medical, LLC | $43.29 | 2022-2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $25.12 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $23.70 | 2025 | Vegzelma |
| Ethicon US, LLC | $20.65 | 2022 | |
| Conmed Corporation | $20.21 | 2025 | Airseal |
| Braintree Laboratories, INC. | $17.13 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.09 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.76 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $13.71 | 2024 | Dificid |
| Ardelyx, INC. | $13.56 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bergquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.